0000014272-20-000040.txt : 20200115 0000014272-20-000040.hdr.sgml : 20200115 20200115170435 ACCESSION NUMBER: 0000014272-20-000040 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200115 DATE AS OF CHANGE: 20200115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VESSEY RUPERT CENTRAL INDEX KEY: 0001677618 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 20528798 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 4/A 1 wf-form4a_157912585811970.xml FORM 4/A X0306 4/A 2019-12-31 2020-01-03 0 0000014272 BRISTOL MYERS SQUIBB CO BMY 0001677618 VESSEY RUPERT 430 E. 29TH STREET 14TH FLOOR NEW YORK NY 10016 0 1 0 0 Pres., Research & Early Dev. Common Stock, $0.10 par value 2019-12-31 4 M 0 16060 0 A 30238 D Common Stock, $0.10 par value 2019-12-31 4 F 0 7910 64.19 D 22328 D Common Stock, $0.10 par value 613 I 401(k) In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Due to an administrative error, this Form 4 is being amended to report in Column 5 the correct number of securities beneficially owned following the reported transaction. Shares withheld for payment of taxes upon vesting of awards. Based on a plan statement as of the end of the third quarter. /s/ Lisa A. Atkins, attorney-in-fact for Rupert Vessey 2020-01-14